ZEBET, BgVV, Diedersdorfer Weg 1, 12277 Berlin, Germany.
Huntingdon Life Sciences, Huntingdon, Cambridgeshire PE18 6ES, UK.
Altern Lab Anim. 2000 May-Jun;28(3):371-401. doi: 10.1177/026119290002800309.
In 1996 and 1997, ECVAM supported a formal validation study on in vitro methods for predicting skin corrosivity. Two of the in vitro tests included in the study employed human skin models, the Skin2™ ZK1350 and EPISKIN™ models. In the ECVAM validation study, BASF, Huntingdon Life Sciences (HLS) and ZEBET tested the Skin2 human skin model, production of which ceased in October 1996, while the validation study was still in progress. Since both of the skin models had shown basic usefulness for corrosivity testing and, in particular, the EPISKIN corrosivity test had proved to be a scientifically valid test, the three laboratories decided to conduct a study to determine whether another commercially available human skin model, EpiDerm™, could also be successfully used to predict skin corrosivity. The study was performed according to the ECVAM prevalidation scheme, to allow for refinement of the test protocol and the prediction model, as well as for independent assessment of the performance of the refined methodology in a final blind trial in the three laboratories. In phase I of the study, ZEBET (Laboratory 1) drafted a Standard Operating Procedure (SOP), including a prediction model (PM1), and the project plan for the study. It was a major task to simplify an existing EpiDerm test protocol, which used the time-course of cytotoxicity as its endpoint. To evaluate the predictivity of the simplified method, which used only a 3-minute exposure to test chemicals, 50 chemicals representing a wide spectrum of chemical entities were tested, revealing that the test sensitivity was too low (65%), whereas the specificity was very high (88%). In addition, acceptance criteria for the negative and positive controls were established. Before proceeding to the next phase of the study, ZEBET distributed a refined SOP, data-recording software and documentation sheets, which allowed Good Laboratory Practice (GLP)-compliant quality assurance for each assay. The main goal of phase II was to produce sufficient data to assess the reproducibility of the EpiDerm skin corrosivity test after transfer to Laboratory 2 (HLS). Repeated testing of several chemicals in both laboratories revealed excellent intralaboratory and interlaboratory reproducibility. In addition, chemicals classified as "non-corrosive" (NC) with a 3-minute exposure in phase I, were re-tested by ZEBET with extended exposure periods of 1 hour and 4 hours. The test sensitivity could be significantly increased, if chemicals classified NC with a 3-minute exposure were tested with a 1-hour exposure. Before proceeding to the final blind trial, a refined SOP was drafted, according to which all chemicals had to be tested with exposure times of 3 minutes and 1 hour, and data for these two exposure times were used in the refined hierarchical prediction model, PM2. In phase III, the blind trial, BASF (Laboratory 3) joined the study. ECVAM selected 24 chemicals from the test chemical set used in the ECVAM skin corrosivity validation study, and BIBRA International (UK) purchased, coded and distributed the chemicals. Each chemical was tested twice, independently, according to the principles of GLP, and coded data were submitted to the Humboldt University (Berlin, Germany) for biostatistical analysis. The analysis revealed that the final test protocol and the refined prediction model (PM2) provided a highly balanced prediction of 88% sensitivity and 86% specificity, which is regarded as the best predictivity an in vitro skin corrosivity test can be expected to achieve. In conclusion, the EpiDerm skin corrosivity test gives an excellent prediction for a wide spectrum of chemicals, and could be used within the context of the new Annex V (EU Dangerous Substances Directive) test method (human skin model assay) for skin corrosion. The results obtained were reproducible, both within and between laboratories, and showed that EpiDerm could be used for testing a wide range of chemicals (both liquids and solids), including organic acids and bases, neutral organics, inorganic acids and bases, electrophiles and phenols. The concordances between the skin corrosivity classifications derived from the in vitro data were very good, and the test was able to distinguish.
1996 年和 1997 年,ECVAM 支持了一项关于预测皮肤腐蚀性的体外方法的正式验证研究。该研究包括两项人类皮肤模型的体外测试,分别是 Skin2™ ZK1350 和 EPISKIN™ 模型。在 ECVAM 的验证研究中,BASF、Huntingdon Life Sciences (HLS) 和 ZEBET 测试了 Skin2 人体皮肤模型,而该模型的生产已于 1996 年 10 月停止,验证研究仍在进行中。由于这两种皮肤模型都显示出对腐蚀性测试的基本有用性,特别是 EPISKIN 腐蚀性测试已被证明是一种科学有效的测试,因此这三个实验室决定进行一项研究,以确定另一种市售的人类皮肤模型 EpiDerm™ 是否也可成功用于预测皮肤腐蚀性。该研究是根据 ECVAM 的预验证方案进行的,旨在改进测试方案和预测模型,并在三个实验室的最终盲法试验中独立评估改进方法的性能。在研究的第一阶段,ZEBET(实验室 1)起草了一份标准操作程序(SOP),包括预测模型(PM1)和项目计划。简化现有的 EpiDerm 测试方案是一项主要任务,该方案使用细胞毒性的时间过程作为其终点。为了评估仅使用 3 分钟暴露于测试化学品的简化方法的预测能力,对 50 种代表广泛化学实体的化学物质进行了测试,结果表明该测试的灵敏度太低(65%),而特异性非常高(88%)。此外,还确定了阴性和阳性对照的接受标准。在进入研究的下一阶段之前,ZEBET 分发了一份经过修订的 SOP、数据记录软件和文档表,这允许每个测定都符合良好实验室规范(GLP)的质量保证。第二阶段的主要目标是产生足够的数据,以评估 EpiDerm 皮肤腐蚀性测试在转移到实验室 2(HLS)后的可重复性。在两个实验室中对几种化学物质进行重复测试,显示出极好的实验室内部和实验室之间的可重复性。此外,在第一阶段中,3 分钟暴露被归类为“非腐蚀性”(NC)的化学物质,ZEBET 用 1 小时和 4 小时的延长暴露期进行了重新测试。如果将归类为 3 分钟暴露 NC 的化学物质用 1 小时暴露进行测试,测试的灵敏度可以显著提高。在进行最终的盲法试验之前,根据修订的 SOP 起草了一份报告,根据该报告,所有化学物质都必须用 3 分钟和 1 小时的暴露时间进行测试,并且这些两个暴露时间的数据都将用于修订后的分层预测模型 PM2 中。在第三阶段,盲法试验中,BASF(实验室 3)加入了研究。ECVAM 从 ECVAM 皮肤腐蚀性验证研究中使用的测试化学物质集中选择了 24 种化学物质,BIBRA International(英国)购买、编码和分发了这些化学物质。每个化学物质都根据 GLP 的原则进行了两次独立测试,并将编码数据提交给德国柏林洪堡大学进行生物统计学分析。分析结果表明,最终的测试方案和修订后的预测模型(PM2)提供了 88%的敏感性和 86%的特异性的高度平衡预测,这被认为是体外皮肤腐蚀性测试可以达到的最佳预测性。总之,EpiDerm 皮肤腐蚀性测试对广泛的化学物质具有极好的预测性,并且可以在新的附件 V(欧盟危险物质指令)测试方法(人体皮肤模型测定)的背景下用于皮肤腐蚀性测试。在实验室内部和实验室之间都可以重复获得结果,并且表明 EpiDerm 可以用于测试广泛的化学物质(包括液体和固体),包括有机酸和碱、中性有机物、无机酸和碱、亲电试剂和酚类。从体外数据得出的皮肤腐蚀性分类之间的一致性非常好,并且该测试能够区分。